Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide (72 mcg or 145 mcg) Administered Orally for 12 Weeks to Patients With Chronic Idiopathic Constipation

Next Previous
Search
Trial Profile

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide (72 mcg or 145 mcg) Administered Orally for 12 Weeks to Patients With Chronic Idiopathic Constipation

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Linaclotide (Primary)
  • Indications Constipation
  • Focus Registrational; Therapeutic Use
  • Sponsors Ironwood Pharmaceuticals

Most Recent Events

  • 26 Jan 2017 According to an Allergan media release, the U.S. Food and Drug Administration (FDA) has approved a 72 mcg dose of LINZESS (linaclotide) for the treatment of chronic idiopathic constipation (CIC) in adult patients.
  • 09 Jun 2016 According to an Ironwood Pharmaceuticals and Allergan media release, based on the results of this trial, the US FDA accepted to review the sNDA for the 72 mcg dose of linaclotide for use in the treatment of adults with chronic idiopathic constipation. The PDUFA target action date is expected in early 2017.
  • 11 Feb 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top